<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007601.ref010">
 <label>10</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Ottosen</surname>
   <given-names>S</given-names>
  </name>, 
  <name>
   <surname>Parsley</surname>
   <given-names>TB</given-names>
  </name>, 
  <name>
   <surname>Yang</surname>
   <given-names>L</given-names>
  </name>, 
  <name>
   <surname>Zeh</surname>
   <given-names>K</given-names>
  </name>, 
  <name>
   <surname>van Doorn</surname>
   <given-names>LJ</given-names>
  </name>, 
  <name>
   <surname>van der Veer</surname>
   <given-names>E</given-names>
  </name>, 
  <etal>et al</etal>
  <article-title>In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122</article-title>. 
  <source>Antimicrob Agents Chemother</source>. 
  <year>2015</year>;
  <volume>59</volume>(
  <issue>1</issue>):
  <fpage>599</fpage>â€“
  <lpage>608</lpage>. Epub 2014/11/12. 
  <pub-id pub-id-type="doi">10.1128/AAC.04220-14</pub-id> ; PubMed Central PMCID: PMCPmc4291405.
  <?supplied-pmid 25385103?>
  <pub-id pub-id-type="pmid">25385103</pub-id>
 </mixed-citation>
</ref>
